Clinical trials: Patients With Diabetes.
Diabetes Mellitus, Type 2
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia
The purpose of the study is to collect information on how Tresiba® works in real world patients. Patients will get Tresiba® as prescribed to them by their study doctor. The study will last for about 6 to 8 months.
- Trial name
- UPDATES (NCT03785522)
- Testing
- Insulin degludec
- Where
- 21 sites in Saudi Arabia
- Volunteers
- 597 people
- Sponsor
- Novo Nordisk A/S
Obesity, Diabetes Mellitus Type 2
Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus
The purpose of this study is to explore the mode of action of topiramate in the treatment of obese and diabetic patients by testing association between genetic variations within candidate genes or chromosomes (thread like…
- Trial name
- NCT00304603
- Testing
- No intervention
- Volunteers
- 1,145 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes (T2DM)
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.
- Trial name
- NCT07387003
- Testing
- GZR101-80, GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)
- Where
- China
- Volunteers
- 345 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Cardiovascular Disease, Diabetes Mellitus, Type 2
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.
- Trial name
- REWIND (NCT01394952)
- Testing
- Dulaglutide
- Where
- 300 sites in United States, Argentina and 23 more
- Volunteers
- 9,901 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Effect of CGM on Glucose Control in Non-insulin-treated Patients With Type 2 Diabetes Mellitus
The clinical value of CGM for diabetic patients undergoing insulin therapy has been widely recognized, but the evidence-based support for its use in non-insulin-treated type 2 diabetic patients remains insufficient.
- Trial name
- CONVERT (NCT06587438)
- Testing
- Sinocare iCan I3 CGM, Sinocare jinzhi+Blood glucose meter
- Where
- 6 sites in China
- Volunteers
- 160 people
- Sponsor
- Sinocare
Type 2 Diabetes
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin therapy) in patients with Type 2 diabetes.
- Trial name
- NCT00952198
- Testing
- ARRY-403, glucokinase activator; oral
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Diabetes Mellitus, Type 2
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
The primary objective of this study is to show that a prandial insulin regimen, consisting of premeal insulin lispro "mid mixture" (or a combined regimen of insulin lispro "mid mixture" and insulin lispro "low mixture") plus…
- Trial name
- NCT00191464
- Testing
- premeal insulin lispro mixtures, insulin glargine, metformin
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Diabetic Foot Ulcer, Diabetic Foot Infection
Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer
This clinical trial evaluates the safety and efficacy of the Nanordica Advanced Antibacterial Wound Dressing (AAWD) in patients suffering from diabetic foot ulcers.
- Trial name
- NM2023 (NCT06667752)
- Testing
- Advanced Antibacterial Wound Dressing, Aquacel Ag+ Extra
- Where
- 11 sites in Estonia, Spain
- Volunteers
- 136 people
- Sponsor
- Nanordica Medical OU
Type 2 Diabetes Mellitus
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin.
- Trial name
- NCT00885352
- Testing
- Sitagliptin, Pioglitazone, Metformin
- Volunteers
- 313 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes
The purpose of this study is to collect important information regarding the glucose-lowering efficacy of MBX-2044 and the safety of MBX-2044 (especially weight gain and edema) in diabetics.
- Trial name
- NCT00422487
- Testing
- MBX-2044
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus
A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to investigate the effects of blocking IL-1 signaling with AMG 108 in type 2 diabetes mellitus patients on glycemic control, as measured by change in HbA1c from baseline to end of treatment (EOT).
- Trial name
- NCT00661921
- Testing
- AMG 108
- Sponsor
- Amgen
Type 2 Diabetes
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with…
- Trial name
- NCT00360334
- Testing
- exenatide, insulin glargine
- Where
- 31 sites in United Kingdom
- Volunteers
- 235 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion [CSII])…
- Trial name
- NCT01109316
- Testing
- Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus and Hypercholesterolemia
A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia
A Study to Compare Rosuvastatin/Ezetimibe Combination and Monotherapy in Patients with Diabetes Mellitus and Hypercholesterolemia.
- Trial name
- NCT03217409
- Testing
- Rosuvastatin+Ezetimibe, Rosuvastatin
- Where
- 4 sites in South Korea
- Volunteers
- 85 people
- Sponsor
- Yuhan Corporation
Type 1 Diabetes Mellitus
The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
This study will enroll eligible subjects into a long-term safety study (Part B). Japanese male and female patients with T1DM and age 18 to 75 years, with inadequate glycemic control on insulin defined as HbA1c ≥ 7.5% and ≤ 10.5%…
- Trial name
- NCT02582814
- Testing
- Dapagliflozin 5 mg, Dapagliflozin 10mg
- Where
- 24 sites in Japan
- Volunteers
- 151 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Diabetes Mellitus Complications
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the effects of RM-131 on gastric emptying, gastroparesis symptoms, and the safety and tolerability of RM-131 compared to placebo in patients with Type 1 and Type 2 diabetes mellitus and…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Trial name
- NCT01571297
- Testing
- RM-131
- Where
- 30 sites in United States
- Volunteers
- 204 people
- Sponsor
- Motus Therapeutics, Inc.
Diabetic Foot, Quality of Life
Patient Empowerment Study
The Patient Empowerment Study is an observational longitudinal study among adults with diabetic foot ulcer (DFU). The scope of this study is to better understand how a patient's DFU disease process and usage of the Podimetrics…
- Conditions
- Diabetic Foot, Quality of Life, Mental Health Wellness 1, Ulcer Foot
- Trial name
- NCT04537676
- Testing
- No intervention, this is an observational study
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Podimetrics, Inc.
Type 2 Diabetes Mellitus, Albuminuria
NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
Primary objective: To characterize the effects of 12 weeks treatment with study drug on albumin-creatinine ratio (ACR) in patients with type 2 diabetes and albuminuria Secondary objectives: To characterize the effect of study…
- Trial name
- NCT01547897
- Testing
- NOX-E36
- Where
- 24 sites in Czechia, Germany and 3 more
- Volunteers
- 76 people
- Sponsor
- TME Pharma AG
Diabetes Mellitus, Non-Insulin-Dependent
The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.
- Trial name
- SUNSHINE (NCT01608724)
- Testing
- Saxagliptin
- Where
- 37 sites in China
- Volunteers
- 2,165 people
- Sponsor
- AstraZeneca
T2DM
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
- Trial name
- CT-L03 (NCT06571591)
- Testing
- CT-L03 Group 1, CT-L03 Group 2, Empagliflozin
- Where
- South Korea
- Volunteers
- 606 people
- Sponsor
- Celltrion
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.